Cargando…

Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension

Despite the increase in therapeutic options, parenteral prostacyclins remain the cornerstone in the medical management of pulmonary arterial hypertension (PAH). While the use of parenteral prostacyclins in pediatric patients is well documented, less is known about alternative drug delivery methods s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Colglazier, Elizabeth, Stevens, Leah, Parker, Claire, Nawaytou, Hythem M., Amin, Elena K., Becerra, Jasmine, Steurer, Martina, Fineman, Jeffrey R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732384/ https://www.ncbi.nlm.nih.gov/pubmed/36514390 http://dx.doi.org/10.1002/pul2.12159

Ejemplares similares

Transition from parenteral prostacyclins to selexipag: safety and feasibility in selected patients
por: Aldweib, Nael, et al.
Publicado: (2021)

Safety and tolerability of continuous inhaled iloprost in critically ill pediatric pulmonary hypertension patients: A retrospective case series
por: Colglazier, Elizabeth, et al.
Publicado: (2023)

Genetics dictating therapeutic decisions in pediatric pulmonary hypertension? A case report suggesting we are getting closer
por: Stevens, Leah, et al.
Publicado: (2022)

Persistence of persistent pulmonary hypertension of the newborn: A case of de novo TBX4 variant
por: Tsoi, Stephanie M., et al.
Publicado: (2022)

Transition from parental prostacyclin to selexipag: a case series of five pulmonary arterial hypertension patients
por: Holthaus, Nathan, et al.
Publicado: (2019)

Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension
por: Momoi, Mizuki, et al.
Publicado: (2022)

Pushing the envelope: a treat and repair strategy for patients with advanced pulmonary hypertension associated with congenital heart disease
por: Kameny, Rebecca Johnson, et al.
Publicado: (2017)

Transitioning Stable Patients with Pulmonary Arterial Hypertension from Parenteral Prostanoids to Oral Selexipag
por: Hinkamp, Colin, et al.
Publicado: (2022)

Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag
por: Kaufmann, Priska, et al.
Publicado: (2015)

Hemodynamic and clinical effects of selexipag in children with pulmonary hypertension
por: Rothman, Abraham, et al.
Publicado: (2020)

First-in-child use of the oral selective prostacyclin IP receptor agonist selexipag in pulmonary arterial hypertension
por: Geerdink, Lianne M., et al.
Publicado: (2017)

Caveolin‐1 associated with severe (pediatric‐onset) presentation of pulmonary arterial hypertension
por: Farrell, Rachel, et al.
Publicado: (2022)

Long‐term safety of a structured transition protocol from parenteral prostanoids to selexipag in pulmonary arterial hypertension
por: Tamura, Yuichi, et al.
Publicado: (2022)

The use of selexipag, a prostacyclin receptor analog, for treatment of severe pulmonary artery hypertension during pregnancy, a case report
por: Khan, Akram, et al.
Publicado: (2023)

Practice patterns of pulmonary hypertension secondary to left heart disease among pediatric pulmonary hypertension providers
por: Nawaytou, Hythem, et al.
Publicado: (2021)

Transitioning selexipag to oral treprostinil in patients with pulmonary artery hypertension
por: Arevalo, Carlo, et al.
Publicado: (2022)

Selexipag for pulmonary arterial hypertension
Publicado: (2021)

Associated radiation exposure from medical imaging and excess lifetime risk of developing cancer in pediatric patients with pulmonary hypertension
por: Mahendra, Malini, et al.
Publicado: (2023)

Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study
por: Coghlan, J. Gerry, et al.
Publicado: (2018)

A thorough QT study in the context of an uptitration regimen with selexipag, a selective oral prostacyclin receptor agonist
por: Hoch, Matthias, et al.
Publicado: (2014)

Case Report: Selexipag in pediatric pulmonary hypertension: Initiation, transition, and titration
por: Faircloth, Jenna M., et al.
Publicado: (2023)

A multicenter, retrospective study of patients with pulmonary arterial hypertension transitioned from parenteral prostacyclin therapy to inhaled iloprost
por: Channick, Richard N., et al.
Publicado: (2013)

Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension
por: Furukawa, Asuka, et al.
Publicado: (2017)

Transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension
por: Oriaku, Ifeoma, et al.
Publicado: (2020)

Corrigendum: Case report: Selexipag in pediatric pulmonary hypertension: initiation, transition, and titration
por: Faircloth, Jenna M., et al.
Publicado: (2023)

Selexipag in the management of pulmonary arterial hypertension: an update
por: Coghlan, J Gerry, et al.
Publicado: (2019)

Selexipag for the treatment of chronic thromboembolic pulmonary hypertension
por: Ogo, Takeshi, et al.
Publicado: (2022)

Patent ductus arteriosus and the risk of bronchopulmonary dysplasia-associated pulmonary hypertension
por: Nawaytou, Hythem, et al.
Publicado: (2023)

Saudi experience in the management of pulmonary arterial hypertension; the outcome of PAH therapy with the exclusion of chronic parenteral prostacyclin
por: Idrees, Majdy, et al.
Publicado: (2015)

Prognosis of pulmonary arterial hypertension patients with pericardial effusion before and after initiation of parenteral prostacyclin therapy
por: Abu‐Rmaileh, Muhammad, et al.
Publicado: (2023)

Sequential combination therapy with parenteral prostacyclin in BMPR2 mutations carriers
por: Boucly, Athénaïs, et al.
Publicado: (2022)

Transitioning intravenous epoprostenol to oral selexipag in idiopathic pulmonary arterial hypertension: a case report
por: Alexandre, André, et al.
Publicado: (2023)

Use of prostacyclin in pulmonary hypertension
por: Vicente, R, et al.
Publicado: (1998)

Role of prostacyclin in pulmonary hypertension
por: Mitchell, Jane A., et al.
Publicado: (2014)

Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy
por: Hardin, Elizabeth Ashley, et al.
Publicado: (2016)

Baseline history of patients using selexipag for pulmonary arterial hypertension
por: Highland, Kristin B., et al.
Publicado: (2019)

Use of selexipag in a teenage patient with pulmonary arterial hypertension
por: Bravo-Valenzuela, Nathalie Jeanne Magioli, et al.
Publicado: (2021)

Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension
por: Gaine, Sean, et al.
Publicado: (2017)

Cost-effectiveness analysis of selexipag for the combined treatment of pulmonary arterial hypertension
por: Dong, Wenxing, et al.
Publicado: (2023)

Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis
por: Song, Ci, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_268q0nrdf2aqb2o00vkn68b6vo